Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep 28;21(36):10299-313.
doi: 10.3748/wjg.v21.i36.10299.

Chronic hepatitis C virus infection and lipoprotein metabolism

Affiliations
Review

Chronic hepatitis C virus infection and lipoprotein metabolism

Yoshio Aizawa et al. World J Gastroenterol. .

Abstract

Hepatitis C virus (HCV) is a hepatotrophic virus and a major cause of chronic liver disease, including hepatocellular carcinoma, worldwide. The life cycle of HCV is closely associated with the metabolism of lipids and lipoproteins. The main function of lipoproteins is transporting lipids throughout the body. Triglycerides, free cholesterol, cholesteryl esters, and phospholipids are the major components of the transported lipids. The pathway of HCV assembly and secretion is closely linked to lipoprotein production and secretion, and the infectivity of HCV particles largely depends on the interaction of lipoproteins. Moreover, HCV entry into hepatocytes is strongly influenced by lipoproteins. The key lipoprotein molecules mediating these interactions are apolipoproteins. Apolipoproteins are amphipathic proteins on the surface of a lipoprotein particle, which help stabilize lipoprotein structure. They perform a key role in lipoprotein metabolism by serving as receptor ligands, enzyme co-factors, and lipid transport carriers. Understanding the association between the life cycle of HCV and lipoprotein metabolism is important because each step of the life cycle of HCV that is associated with lipoprotein metabolism is a potential target for anti-HCV therapy. In this article, we first concisely review the nature of lipoprotein and its metabolism to better understand the complicated interaction of HCV with lipoprotein. Then, we review the outline of the processes of HCV assembly, secretion, and entry into hepatocytes, focusing on the association with lipoproteins. Finally, we discuss the clinical aspects of disturbed lipid/lipoprotein metabolism and the significance of dyslipoproteinemia in chronic HCV infection with regard to abnormal apolipoproteins.

Keywords: Apolipoprotein; Dyslipoproteinemia; Hepatitis C virus; Lipo-viral particle; Lipoprotein.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure of a lipoprotein (very-low-density lipoprotein).
Figure 2
Figure 2
Overview of lipoprotein metabolism. HDLs: High-density lipoproteins; LDLs: Low-density lipoproteins; VLDL: Very-low-density lipoproteins.
Figure 3
Figure 3
Two types of infectious hepatitis C virus-lipo-viral particles: True hepatitis C virus-lipo-viral particles (left) and transient hepatitis C virus-lipo-viral particles (right). HCV: Hepatitis C virus.
Figure 4
Figure 4
Attachment of hepatitis C virus-lipo-viral particles to the surface of hepatocyte. HCV-LVP: Hepatitis C virus-lipo-viral particles; HSPGs: Heparan sulfate proteoglycans; LDLs: Low-density lipoproteins.

References

    1. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med. 2013;19:837–849. - PMC - PubMed
    1. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61:S58–S68. - PubMed
    1. Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group; HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security. Int J Technol Assess Health Care. 2005;21:55–65. - PubMed
    1. Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV) Curr HIV/AIDS Rep. 2015;12:68–78. - PMC - PubMed
    1. Popescu CI, Riva L, Vlaicu O, Farhat R, Rouillé Y, Dubuisson J. Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) 2014;3:892–921. - PMC - PubMed

LinkOut - more resources